Novartis Asks Fed. Circ. To Revive MS Treatment Patent
Novartis AG asked a Federal Circuit panel to set aside a Patent Trial and Appeal Board decision that invalidated its multiple sclerosis treatment Gilenya on Thursday, pushing the judges to find...To view the full article, register now.
Already a subscriber? Click here to view full article